By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park
Room 561
New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


Drug Discovery

Company News
Melinta Announces FDA Acceptance of Investigational New Drug Application for Topical Radezolid 3/2/2017 9:44:09 AM
Melinta And Menarini Group Enter Into Commercial And Co-Development Agreement For Delafloxacin In 68 Countries 3/2/2017 9:41:40 AM
Melinta New Drug Application For Baxdela Accepted For Filing By FDA 1/5/2017 7:35:14 AM
Ligand (LGND) Partner Melinta Submits Baxdela New Drug Application For Hospital-Treated Skin Infections 10/24/2016 8:43:25 AM
Melinta's Baxdela Successfully Achieves Primary Endpoints in Late Stage Study 5/12/2016 7:07:31 AM
Melinta Appoints Dr. Eugene Sun As Chief Executive Officer 4/19/2016 8:02:22 AM
Melinta Appoints John Temperato President And Chief Operating Officer 2/23/2016 8:04:57 AM
Melinta Presents Complete Delafloxacin Results From Phase III Study In Patients With Acute Bacterial Skin And Skin Structure Infections At ID Week 10/12/2015 7:09:07 AM
Melinta Banks $67 Million for Skin Infection Antibiotic 6/10/2015 6:50:45 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Joins White House Forum On Antibiotic Stewardship In Commitment To Take Steps To Avert Potential Crisis 6/2/2015 11:05:32 AM